STAT

Muscle and fat loss may offer clues to pancreatic cancer’s deadly ways

Muscle and fat loss might offer clues to understanding pancreatic cancer and diagnosing it earlier, a new study suggests.
Pancreatic cancer cells

Of all the places to get cancer, the pancreas may be the worst. Difficult to detect and nearly impossible to treat, pancreatic cancer is the only major cancer with a five-year survival rate below 10 percent. New research, published Wednesday in Nature, challenges some widely held assumptions about the disease and could eventually help doctors diagnose patients earlier, when treatments are most effective.

The study’s findings came from investigating how early pancreatic tumors affect peripheral tissues — mainly muscle and fat — in both mice and humans.

Doctors have long observed that many pancreatic cancer patients experience debilitating tissue wasting. Researchers have been working to stop or even reverse such loss, although they still

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

Related